{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:00:02Z","timestamp":1790683202837,"version":"4.1.0"},"reference-count":156,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1), its ligand (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) have revolutionized oncology, yet they unleash a unique spectrum of inflammatory toxicities known as immune-related adverse events (irAEs). Cutaneous and gastrointestinal irAEs represent the most frequent and clinically challenging manifestations encountered by allergists and clinical immunologists. Unlike classical type I\u2013IV hypersensitivity reactions, irAEs arise from disruption of peripheral immune tolerance, leading to T-cell hyperactivation, B-cell dysregulation with IgE and IgG4 skewing, and pro-inflammatory cytokine networks dominated by interleukin (IL)-6, IL-17, and interferon-gamma. IrAEs are best conceptualized as a distinct category of drug-induced autoimmunity, rather than a fifth type of hypersensitivity reaction. This review provides a comprehensive, clinically actionable framework for the practicing allergist. We dissect the divergent pathophysiology of anti-CTLA-4 versus anti-PD-1 toxicities, characterize the full spectrum of cutaneous eruptions and delineate the grading and management of ICI-induced colitis, which mimics inflammatory bowel disease but has distinct immune signatures. We critically evaluate emerging biomarkers (eosinophilia, serum IL-6, and fecal calprotectin) and present an evidence-based algorithm for step-up therapy: from topical corticosteroids and antihistamines for grade 1\u20132 rash, to systemic corticosteroids for grade 2\u20133 colitis, and biologic agents (infliximab, vedolizumab, tocilizumab, dupilumab) for corticosteroid-refractory cases. A dedicated section tackles the allergist\u2019s most challenging dilemma (rechallenge after severe irAEs) providing evidence-based guidance. We identify critical knowledge gaps: pre-existing atopy as a risk factor, antihistamine prophylaxis utility, and overlapping toxicity management. This review repositions allergists as essential oncology partners, advancing irAE care from crisis response to precision immuno-toxicology.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1914702","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:23:14Z","timestamp":1790680994000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune checkpoint inhibitors and the inflammatory dysregulation: decoding cutaneous and gastrointestinal immune-related adverse events for the allergist and immunologist"],"prefix":"10.3389","volume":"17","author":[{"given":"Muhammad","family":"Wasim","sequence":"first","affiliation":[{"name":"Maternal and Children\u2019s Health Research Institute, Shunde Women and Children\u2019s Hospital, Guangdong Medical University","place":["Foshan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoda","family":"Ma","sequence":"additional","affiliation":[{"name":"Maternal and Children\u2019s Health Research Institute, Shunde Women and Children\u2019s Hospital, Guangdong Medical University","place":["Foshan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Shunde Women and Children Hospital, Guangdong Medical University","place":["Foshan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70412","article-title":"The role of immune checkpoint inhibitors in cancer therapy: mechanism and therapeutic advances","volume":"6","author":"Chen","year":"2025","journal-title":"MedComm"},{"key":"B3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s12672-025-04361-7","article-title":"Immune checkpoint blockade in cancer: current insights and future horizons","volume":"17","author":"Saman","year":"2026","journal-title":"Discover Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1686568","article-title":"Advancements in the utilization of immune checkpoint inhibitors for the treatment of gynecological tumors","volume":"17","author":"Su","year":"2026","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin","year":"2023","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1447021","article-title":"Toxicity in the era of immune checkpoint inhibitor therapy","volume":"15","author":"Keam","year":"2024","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30050355","article-title":"Adverse effects of immune-checkpoint inhibitors: a comprehensive imaging-oriented review","volume":"30","author":"Mallio","year":"2023","journal-title":"Curr Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2026.104341","article-title":"Neurological immune-related adverse events of immune-checkpoint inhibitors: an updated review","volume":"55","author":"Picca","year":"2026","journal-title":"La Presse M\u00e9dicale"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118669","article-title":"Neurologic complications of immune checkpoint inhibitors: a comprehensive review","volume":"192","author":"Lashkajani","year":"2025","journal-title":"BioMed Pharmacother"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8111777","article-title":"Neurological immune related adverse events associated with nivolumab, ipilimumab, and pembrolizumab therapy-review of the literature and future outlook","volume":"8","author":"M\u00f6hn","year":"2019","journal-title":"J Clin Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13375","article-title":"Neurological immune-related adverse events associated with immune checkpoint inhibitors: a review of the literature","volume":"16","author":"Fan","year":"2020","journal-title":"Asia Pac J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2025.105938","article-title":"Practical management of rheumatic immune-related adverse events occurring with immune checkpoint inhibitors: a narrative review","volume":"93","author":"Tison","year":"2026","journal-title":"Joint Bone Spine"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065643","article-title":"Rheumatic immune-related adverse events due to immune checkpoint inhibitors-a 2023 update","volume":"24","author":"Dang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.08.063","article-title":"AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review","volume":"160","author":"Dougan","year":"2021","journal-title":"Gastroenterology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.7326\/aitc202402200","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16071440","article-title":"Immune-related adverse events due to cancer immunotherapy: immune mechanisms and clinical manifestations","volume":"16","author":"Casagrande","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41573-021-00259-5","article-title":"Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies","volume":"21","author":"Sullivan","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-014622","article-title":"Heterogeneous survival impact of immune-related adverse events in US veterans","volume":"14","author":"Rehmani","year":"2026","journal-title":"J Immunother Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/cji.0000000000000300","article-title":"Immune-related adverse events and survival in solid tumors treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"43","author":"Petrelli","year":"2020","journal-title":"J Immunother"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000875","article-title":"Impact of immune-related adverse events on survival in patients with gastrointestinal cancer treated with immune checkpoint inhibitors: a meta-analysis","volume":"16","author":"Han","year":"2025","journal-title":"Clin Trans Gastroenterol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0179","article-title":"Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: a meta-analysis","volume":"13","author":"Dall'Olio","year":"2021","journal-title":"Immunotherapy"},{"key":"B27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ejca.2020.03.017","article-title":"Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors","volume":"132","author":"Maillet","year":"2020","journal-title":"Eur J Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nri3108","article-title":"The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses","volume":"11","author":"Walker","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ccell.2018.02.010","article-title":"Fc effector function contributes to the activity of human anti-CTLA-4 antibodies","volume":"33","author":"Arce Vargas","year":"2018","journal-title":"Cancer Cell"},{"key":"B32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40425-015-0081-1","article-title":"Baseline circulating IL-17 predicts toxicity while TGF-\u03b21 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma","volume":"3","author":"Tarhini","year":"2015","journal-title":"J Immunother Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/978-3-0348-0522-3_6","article-title":"Regulatory T cells vs Th17: differentiation of Th17 versus Treg, are the mutually exclusive","volume":"2","author":"Zheng","year":"2013","journal-title":"Am J Clin Exp Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/coc.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.vaccine.2006.10.049","article-title":"CD4+ T\u00a0cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapy","volume":"57","author":"Franken","year":"2024","journal-title":"Immunity"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13341","article-title":"The role of IL-6 in immunotherapy of non-small cell lung cancer (NSCLC) with immune-related adverse events (irAEs)","volume":"11","author":"Ke","year":"2020","journal-title":"Thorac Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1553882","article-title":"Serum IL-6 predicts immunotherapy-related adverse and outcome in advanced gastric and esophageal cancer patients with anti-PD-1 treatment","volume":"16","author":"Ma","year":"2025","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx081","article-title":"Colon immune-related adverse events: anti-CTLA-4 and anti-PD-1 blockade induce distinct immunopathological entities","volume":"11","author":"Coutzac","year":"2017","journal-title":"J Crohns Colitis"},{"key":"B39","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.12.034","article-title":"Defining T cell states associated with response to checkpoint immunotherapy in melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-25-3352","article-title":"When checkpoint inhibitors break barriers: mechanisms and challenges of irAEs of the skin, gastrointestinal tract, and lung","volume":"32","author":"Sinha","year":"2026","journal-title":"Clin Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1108116","article-title":"Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events","volume":"14","author":"M\u00fcller-Jensen","year":"2023","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1159\/000547431","article-title":"Immune checkpoint inhibitor-induced bullous pemphigoid: successful treatment with dupilumab while maintaining immunotherapy","volume":"18","author":"Florea","year":"2025","journal-title":"Case Rep Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/antib12040070","article-title":"Elevated IgE levels-an allergy or an underlying inborn error of immunity in children with recurrent infections","volume":"12","author":"Kostova","year":"2023","journal-title":"Antibodies (Basel)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx108","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab","volume":"28","author":"Chaput","year":"2017","journal-title":"Ann Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0238-9","article-title":"Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis","volume":"24","author":"Wang","year":"2018","journal-title":"Nat Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2021.03.008","article-title":"Hypersensitivity reactions and anaphylaxis to checkpoint inhibitor-monoclonal antibodies and desensitization","volume":"126","author":"Labella","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.12.009","article-title":"Anaphylactic reaction to checkpoint inhibitors with confirmed hypersensitivity to polysorbate 80","volume":"11","author":"Podevin","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.04.105","article-title":"Dermatologic toxicities to immune checkpoint inhibitor therapy: a review of histopathologic features","volume":"83","author":"Ellis","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1071983","article-title":"Cutaneous manifestations associated with immune checkpoint inhibitors","volume":"14","author":"Watanabe","year":"2023","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3779\/j.issn.1009-3419.2019.10.06","article-title":"Management of dermatologic toxicities related to immune checkpoint inhibitors","volume":"22","author":"Si","year":"2019","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.02141","article-title":"Treatment outcomes of immune-related cutaneous adverse events","volume":"37","author":"Phillips","year":"2019","journal-title":"J Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40425-018-0323-0","article-title":"Granulomatous\/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients","volume":"6","author":"Tetzlaff","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.632683","article-title":"Causes of pruritus in patients treated with immune checkpoint inhibitors for melanomas or skin carcinomas","volume":"8","author":"Salinas","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcskn.2026.101128","article-title":"Rapid reduction of immune checkpoint inhibitor\u2013associated pruritus with nemolizumab","volume":"4","author":"Kreft","year":"2026","journal-title":"EJC Skin Cancer"},{"key":"B56","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.lungcan.2017.04.020","article-title":"Aprepitant for refractory nivolumab-induced pruritus","volume":"109","author":"Ito","year":"2017","journal-title":"Lung Cancer"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4790810","article-title":"Aprepitant for the treatment of chronic refractory pruritus","volume":"2017","author":"He","year":"2017","journal-title":"BioMed Res Int"},{"key":"B58","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3390\/dermatopathology9010010","article-title":"Bullous pemphigoid in patients receiving immune-checkpoint inhibitors and psoriatic patients-focus on clinical and histopathological variation","volume":"9","author":"Niebel","year":"2022","journal-title":"Dermatopathology (Basel)"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1745011","article-title":"Immune checkpoint inhibitor-induced bullous pemphigoid: a systematic review of clinical characteristics and outcomes based on case reports","volume":"17","author":"Chang","year":"2026","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/cia2.12126","article-title":"Doxycycline as an initial treatment of bullous pemphigoid in Japanese patients","volume":"3","author":"Kimura","year":"2020","journal-title":"J Cutaneous Immunol Allergy"},{"key":"B61","doi-asserted-by":"publisher","first-page":"Cd002292","DOI":"10.1002\/14651858.cd002292.pub4","article-title":"Interventions for bullous pemphigoid","volume":"8","author":"Singh","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2021.102799","article-title":"A blistering new era for bullous pemphigoid: a scoping review of current therapies, ongoing clinical trials, and future directions","volume":"70","author":"Khalid","year":"2021","journal-title":"Ann Med Surg (Lond)"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.2147\/ccid.s487711","article-title":"Successful treatment of immune checkpoint inhibitor-induced bullous pemphigoid with omalizumab: a case report and review of the literature","volume":"17","author":"Chen","year":"2024","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60020270","article-title":"Rituximab in the management of autoimmune bullous diseases: a treatment-resistant case series from a single central European referral center","volume":"60","author":"Spa\u0142ek","year":"2024","journal-title":"Med (Kaunas)"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf208","article-title":"Immuno-oncologyDupilumab for bullous pemphigoid related to immune checkpoint inhibitors: a retrospective case series","volume":"30","author":"Nykaza","year":"2025","journal-title":"Oncologist"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.2428","article-title":"Evaluation of dupilumab in patients with bullous pemphigoid","volume":"159","author":"Zhao","year":"2023","journal-title":"JAMA Dermatol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s44272-025-00043-1","article-title":"Multi-disciplinary expert consensus on cutaneous adverse events caused by immune checkpoint inhibitors (2025)","volume":"4","author":"Sun","year":"2025","journal-title":"Clin Cancer Bull"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.17235\/reed.2024.10250\/2024","article-title":"Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: position statement of the AEEH-AEG-SEPD-SEOM-GETECCU","volume":"47","author":"Riveiro-Barciela","year":"2024","journal-title":"Gastroenterol Hepatol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.953546","article-title":"Hemidesmosomal reactivity and treatment recommendations in immune checkpoint inhibitor-induced bullous pemphigoid-a retrospective, monocentric study","volume":"13","author":"Schauer","year":"2022","journal-title":"Front Immunol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.anai.2022.05.009","article-title":"Etanercept treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"129","author":"Tian","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/1503709","article-title":"Treatments for severe cutaneous adverse reactions","volume":"2017","author":"Cho","year":"2017","journal-title":"J Immunol Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.s163391","article-title":"Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies","volume":"10","author":"Chen","year":"2018","journal-title":"Cancer Manag Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002879","article-title":"Nivolumab-associated DRESS in a genetic susceptible individual","volume":"9","author":"Ai","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2022.100673","article-title":"DRESS syndrome: a literature review and treatment algorithm","volume":"16","author":"Calle","year":"2023","journal-title":"World Allergy Organ J"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J Clin Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14011","article-title":"Anti-PD1-induced psoriasis: a study of 21 patients","volume":"31","author":"Bonigen","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41598-024-84488-9","article-title":"Clinical outcomes of endocrine and other disorders induced by immune checkpoint inhibitors in Japanese patients","volume":"15","author":"Iwamoto","year":"2025","journal-title":"Sci Rep"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-025-00349-z","article-title":"Clinical management and outcomes of immune-related adverse events during treatment with immune checkpoint inhibitor therapies in melanoma and renal cell carcinoma: a UK real-world evidence study","volume":"13","author":"Olsson-Brown","year":"2025","journal-title":"Oncol Ther"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-091708","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events: a retrospective study from VigiBase update in 2024 looking for emergent safety signals","volume":"14","author":"Orphelin","year":"2024","journal-title":"BMJ Open"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2023.2188487","article-title":"Targeting interleukin 4 and interleukin 13: a novel therapeutic approach in bullous pemphigoid","volume":"55","author":"Chen","year":"2023","journal-title":"Ann Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae134","article-title":"Safety, efficacy, and survival outcomes of immune checkpoint inhibitors rechallenge in patients with cancer: a systematic review and meta-analysis","volume":"29","author":"Liu","year":"2024","journal-title":"Oncologist"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2025.2543510","article-title":"Immune-related hepatitis and hypophysitis are associated with superior survival in melanoma patients treated with combined ipilimumab and nivolumab","volume":"14","author":"Al Remawi","year":"2025","journal-title":"Oncoimmunology"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2017.1344805","article-title":"Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: a systematic review and meta-analysis","volume":"6","author":"Wang","year":"2017","journal-title":"Oncoimmunology"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01547","article-title":"Checkpoint blockade toxicity and immune homeostasis in the gastrointestinal tract","volume":"8","author":"Dougan","year":"2017","journal-title":"Front Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1111\/den.12820","article-title":"Endoscopic findings of ipilimumab-induced colitis","volume":"29","author":"Satoh","year":"2017","journal-title":"Dig Endosc"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000000829","article-title":"Histopathologic features of colitis due to immunotherapy with anti-PD-1 antibodies","volume":"41","author":"Chen","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1111\/his.14248","article-title":"Medication-specific variations in morphological patterns of injury in immune check-point inhibitor-associated colitis","volume":"78","author":"Isidro","year":"2021","journal-title":"Histopathology"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4393","article-title":"Infectious complications of immune checkpoint inhibitors in solid organ Malignancies","volume":"11","author":"Ross","year":"2022","journal-title":"Cancer Med"},{"key":"B89","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1183\/13993003.congress-2024.pa5116","article-title":"Incidence and risk factors of serious infections occurred in patients with lung cancer following immune checkpoint blockade therapy","volume":"25","author":"Wang","year":"2025","journal-title":"BMC Cancer"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16101919","article-title":"Outcomes of budesonide as a treatment option for immune checkpoint inhibitor-related colitis in patients with cancer","volume":"16","author":"Machado","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B91","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s40425-019-0756-0","article-title":"Budesonide treatment for microscopic colitis from immune checkpoint inhibitors","volume":"7","author":"Hughes","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0057","article-title":"NCCN Guidelines\u00ae Insights: management of immunotherapy-related toxicities, version 2.2024","volume":"22","author":"Thompson","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.16_suppl.e14650","article-title":"Biologics in the treatment of immune-related adverse events: a systematic review","volume":"43","author":"Fleshner","year":"2025","journal-title":"J Clin Oncol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s40257-024-00866-z","article-title":"The use of biologic agents for the treatment of cutaneous immune-related adverse events from immune checkpoint inhibitors: a review of reported cases","volume":"25","author":"Pach","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008232","article-title":"Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series","volume":"12","author":"Harvey","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1623150","article-title":"Risk factors for steroid-refractory in immune checkpoint inhibitor-induced colitis: a retrospective cohort study","volume":"16","author":"Meng","year":"2025","journal-title":"Front Immunol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-1962-6","article-title":"Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis","volume":"66","author":"Bergqvist","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v10.i29.10550","article-title":"Vedolizumab in the treatment of immune checkpoint inhibitor-induced colitis: two case reports","volume":"10","author":"Zhang","year":"2022","journal-title":"World J Clin cases"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000474","article-title":"Fecal microbiota transplantation for immune checkpoint inhibitor-induced colitis is safe and contributes to recovery: two case reports","volume":"46","author":"Groenewegen","year":"2023","journal-title":"J Immunother"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-24-2150","article-title":"Treatment of immune checkpoint inhibitor-related colitis: a narrative review","volume":"13","author":"Wang","year":"2024","journal-title":"Transl Cancer Res"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.70293","article-title":"Tocilizumab mitigates immune checkpoint inhibitor\u2013induced colitis and inhibits tumor growth by targeting the IL-6-JAK2-STAT3 signaling pathway","volume":"41","author":"Chen","year":"2026","journal-title":"J Gastroenterol Hepatol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000001162","article-title":"A potential new use for tocilizumab: Refractory checkpoint inhibitor hepatitis","volume":"10","author":"Lyles","year":"2023","journal-title":"ACG Case Rep J"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3390\/ph16111548","article-title":"IL12\/23 blockade with ustekinumab as a treatment for immune-related cutaneous adverse events","volume":"16","author":"Gu","year":"2023","journal-title":"Pharm (Basel)"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.09.034","article-title":"Immune checkpoint inhibitor-induced colitis","volume":"168","author":"A","year":"2025","journal-title":"Gastroenterology"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00584-4","article-title":"TNF in the era of immune checkpoint inhibitors: Friend or foe","volume":"17","author":"Chen","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252010919","article-title":"Balancing tumor immunotherapy and immune-related adverse events: Unveiling the key regulators","volume":"25","author":"Huang","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1499478","article-title":"Impact of steroid-sparing immunosuppressive agents on tumor outcome in the context of cancer immunotherapy with highlight on melanoma: A systematic literature review and meta-analysis","volume":"15","author":"Strouse","year":"2024","journal-title":"Front Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-022-00852-7","article-title":"Update on immune checkpoint inhibitor enterocolitis","volume":"24","author":"Kelly-Goss","year":"2022","journal-title":"Curr Gastroenterol Rep"},{"key":"B109","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1007\/s00520-024-08889-2","article-title":"Immune checkpoint inhibitor-induced diarrhea and colitis: An overview","volume":"32","author":"Zoghbi","year":"2024","journal-title":"Support Care Cancer"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009051","article-title":"Open-capsule budesonide for the treatment of immune-related enteritis from checkpoint inhibitors","volume":"12","author":"Magahis","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-023-01094-6","article-title":"Diagnosis and pharmacological management of microscopic colitis in geriatric care","volume":"41","author":"Nielsen","year":"2024","journal-title":"Drugs Aging"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26010088","article-title":"Immune checkpoint inhibitor-associated cutaneous adverse events: Mechanisms of occurrence","volume":"26","author":"Eshaq","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-026-04660-y","article-title":"Risk assessment of asthma and allergic rhinitis in atopic dermatitis patients treated with biologics and JAK inhibitors: A systematic review and network meta-analysis of randomized controlled trials","volume":"24","author":"Zeng","year":"2026","journal-title":"BMC Med"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-026-01260-x","article-title":"Reframing eczema: Th2-skewed contact sensitization, atopy patch testing, and systemic contact dermatitis","volume":"26","author":"Jacob","year":"2026","journal-title":"Curr Allergy Asthma Rep"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-025-01261-2","article-title":"Type 2 immunity in allergic diseases","volume":"22","author":"Ogulur","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1207544","article-title":"Cutaneous immune-related adverse events to immune checkpoint inhibitors: From underlying immunological mechanisms to multi-omics prediction","volume":"14","author":"Cao","year":"2023","journal-title":"Front Immunol"},{"key":"B117","article-title":"Cutaneous toxicities of immune checkpoint inhibitors: The role of the dermatologist","volume":"93","author":"Tattersall","year":"2020","journal-title":"Yale J Biol Med"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17121992","article-title":"Immune-related cutaneous adverse events display distinct clinical and molecular characteristics, depending on immune checkpoints targeted","volume":"17","author":"Kraehenbuehl","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B119","doi-asserted-by":"publisher","first-page":"Fso608","DOI":"10.2144\/fsoa-2020-0070","article-title":"A retrospective analysis of eosinophilia as a predictive marker of response and toxicity to cancer immunotherapy","volume":"6","author":"Krishnan","year":"2020","journal-title":"Future Sci OA"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.3390\/immuno1030017","article-title":"Eosinophil count as predictive biomarker of immune-related adverse events (irAEs) in immune checkpoint inhibitors (ICIs) therapies in oncological patients","volume":"1","author":"Giommoni","year":"2021","journal-title":"Immuno"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.22541\/au.159863177.79676202","article-title":"The clinical and histopathological features of cutaneous immune-related adverse events and their outcomes","volume":"10","author":"Hashimoto","year":"2021","journal-title":"J Clin Med"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.70022","article-title":"Eosinophilic reactive airways disease after immune checkpoint inhibitor treatment","volume":"12","author":"Cordial","year":"2024","journal-title":"Respirol Case Rep"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1079034","article-title":"Case report: Successful use of mepolizumab for immune checkpoint inhibitors-induced hypereosinophilic syndrome in two patients with solid Malignancies","volume":"13","author":"Lazzari","year":"2023","journal-title":"Front Oncol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2021.101520","article-title":"Mepolizumab and dupilumab as a replacement to systemic glucocorticoids for the treatment of chronic eosinophilic pneumonia and allergic bronchopulmonary aspergillosis - Case series, Almoosa specialist hospital","volume":"34","author":"Eldaabossi","year":"2021","journal-title":"Respir Med Case Rep"},{"key":"B125","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13256-023-04255-8","article-title":"When sequential use of mepolizumab and dupilumab in a severe atopic eosinophilic asthmatic questions the role of eosinophils in mediating the clinical expression of the disease: A case report","volume":"18","author":"Sabbe","year":"2024","journal-title":"J Med Case Rep"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1080\/1750743x.2025.2527589","article-title":"IgE-mediated anaphylaxis induced by pembrolizumab","volume":"17","author":"Legroux","year":"2025","journal-title":"Immunotherapy"},{"key":"B127","article-title":"Management of steroid-refractory immune-related adverse events","volume":"33","author":"Watson","year":"2019","journal-title":"Oncol (Williston Park)"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-5088-7_1","article-title":"Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: Relationship to dose, antihistamine pretreatment, and infusion number","volume":"31","author":"Wasserman","year":"2004","journal-title":"J Rheumatol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1159\/000547015","article-title":"Vedolizumab: Beyond inflammatory bowel disease","volume":"34","author":"Li","year":"2025","journal-title":"Med Princ Pract"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03447-6","article-title":"Comparative efficacy and safety of advanced therapies in maintenance treatment of adult patients with moderate-to-severe Crohn\u2019s disease: A systematic literature review and network meta-analysis","volume":"43","author":"Schreiber","year":"2026","journal-title":"Adv Ther"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14134419","article-title":"Efficacy and safety of infliximab and vedolizumab maintenance therapy in patients with Crohn's disease and ulcerative colitis: A systematic review and meta-analysis","volume":"14","author":"Sands","year":"2025","journal-title":"J Clin Med"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.5146","article-title":"Tocilizumab for corticosteroid-refractory immune checkpoint inhibitor-induced generalized morphea","volume":"159","author":"Blaise","year":"2023","journal-title":"JAMA Dermatol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.2147\/btt.s367675","article-title":"Biologic therapy for refractory immune checkpoint inhibitor colitis","volume":"16","author":"Alorfi","year":"2022","journal-title":"Biologics"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1097\/cmr.0000000000000969","article-title":"Tocilizumab in the treatment of steroid refractory immune-related hepatotoxicity: A case series and review of the literature","volume":"34","author":"Ozluk","year":"2024","journal-title":"Melanoma Res"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.cgh.2023.12.011","article-title":"Tofacitinib is effective in treating refractory immune checkpoint inhibitor hepatitis","volume":"22","author":"Wang","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1080\/1744666x.2022.2014323","article-title":"The infection risks of JAK inhibition","volume":"18","author":"Adas","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.913217","article-title":"Fecal microbiota transplantation effectively cures a patient with severe bleeding immune checkpoint inhibitor-associated colitis and a short review","volume":"12","author":"Chen","year":"2022","journal-title":"Front Oncol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1129730","article-title":"Pneumocystis jirovecii pneumonia associated with immune checkpoint inhibitors: A systematic literature review of published case reports and disproportionality analysis based on the FAERS database","volume":"14","author":"Xia","year":"2023","journal-title":"Front Pharmacol"},{"key":"B139","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1177\/1753465810380102","article-title":"Update on the diagnosis and treatment of Pneumocystis pneumonia","volume":"5","author":"Carmona","year":"2011","journal-title":"Ther Adv Respir Dis"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-21-2764","article-title":"Herpes zoster in lung cancer patients treated with PD-1\/PD-L1 inhibitors","volume":"11","author":"Taoka","year":"2022","journal-title":"Transl Cancer Res"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.5415\/apallergy.0000000000000138","article-title":"Successful desensitization to atezolizumab-induced near-fatal anaphylaxis in patients with hepatocellular carcinoma: A case report and literature review","volume":"14","author":"Oh","year":"2024","journal-title":"Asia Pac Allergy"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez308","article-title":"Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors","volume":"58","author":"Weinmann","year":"2019","journal-title":"Rheumatol (Oxford)"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202048747","article-title":"Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action","volume":"51","author":"Willsmore","year":"2021","journal-title":"Eur J Immunol"},{"key":"B145","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1001\/jamaoncol.2020.3946","article-title":"Recurrence of immune-related adverse events after immune checkpoint inhibitor rechallenge","volume":"6","author":"Zheng","year":"2020","journal-title":"JAMA Oncol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyaf200","article-title":"Efficacy and safety of immune checkpoint inhibitor rechallenge following immune-related adverse events: A review","volume":"56","author":"Mizuno","year":"2026","journal-title":"Jpn J Clin Oncol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.730320","article-title":"Safety and efficacy of the rechallenge of immune checkpoint inhibitors after immune-related adverse events in patients with cancer: A systemic review and meta-analysis","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-2795","article-title":"Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy","volume":"25","author":"Lim","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010638","article-title":"Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse events","volume":"13","author":"Khattab","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1741482","article-title":"Impact of immune-related adverse events on treatment outcomes in advanced esophageal squamous cell carcinoma treated with immune checkpoint inhibitors","volume":"17","author":"Zhang","year":"2026","journal-title":"Front Immunol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02887-1","article-title":"Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review","volume":"132","author":"Jayathilaka","year":"2025","journal-title":"Br J Cancer"},{"key":"B152","doi-asserted-by":"publisher","first-page":"e2352302","DOI":"10.1001\/jamanetworkopen.2023.52302","article-title":"Immune-related adverse events and survival among patients with metastatic NSCLC treated with immune checkpoint inhibitors","volume":"7","author":"Cook","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17030403","article-title":"Immunotherapy-related adverse events and clinical outcomes in adult solid-tumor patients admitted to an onco-hospitalist medicine service","volume":"17","author":"Simbaqueba Clavijo","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B154","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1053\/j.gastro.2023.03.230","article-title":"Low-dose interleukin 2 for the treatment of moderate to severe ulcerative colitis","volume":"165","author":"Allegretti","year":"2023","journal-title":"Gastroenterology"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1227833","article-title":"Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy","volume":"14","author":"Chakraborty","year":"2023","journal-title":"Front Immunol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003731","article-title":"Anti-CCR4 treatment depletes regulatory T cells and leads to clinical activity in a canine model of advanced prostate cancer","volume":"10","author":"Maeda","year":"2022","journal-title":"J Immunother Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1914702\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:23:17Z","timestamp":1790680997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1914702\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":156,"alternative-id":["10.3389\/fimmu.2026.1914702"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1914702","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"article-number":"1914702"}}